Optimizing Cancer Drug Treatments Using Big Data Integration of Genomic and Clinical Data for Personalized Medicine [0.03%]
利用大数据整合基因组和临床数据优化癌症药物治疗的个性化医疗研究
Amruta Mohan Chimanna (Umrani),Harshala Shingne,Shabana Pathan et al.
Amruta Mohan Chimanna (Umrani) et al.
Personalized cancer care depends on the seamless integration of genetic profiles, medical histories, and continuous patient monitoring to optimize therapeutic outcomes. Current clinical strategies struggle to combine these disparate, highly...
The Effect of Melatonin on Sleep Quality, Anxiety, and Depression in Patients with Primary Breast Cancer Undergoing Adjuvant Chemotherapy Type: A Randomized, Double-Blind, Placebo-Controlled Trial [0.03%]
褪黑素对接受辅助化疗的一原发性乳腺癌患者睡眠质量、焦虑和抑郁的影响：一项随机双盲对照试验
Mohsen SeddighShamsi,Mohsen Esfandbod,Shabnam Jalali et al.
Mohsen SeddighShamsi et al.
This study aimed to evaluate the effect of melatonin on sleep Quality, anxiety, and depression in the patients with primary breast cancer undergoing adjuvant chemotherapy in a double-blind, placebo-controlled trial. Forty patients with stag...
A Comparative Analysis of TIRADS and ATA Classification Systems in Determining the Malignancy of Thyroid Nodules [0.03%]
TIRADS和ATA分类系统在判定甲状腺结节恶性方面的比较分析
Rahil Rahimi,Hamid Moradi,Mohammadreza Azimi Aval et al.
Rahil Rahimi et al.
The present study aims to compare the diagnostic performance of two ultrasound classifications of thyroid nodules: 2015 American Thyroid Association (ATA) guidelines and 2017 American College of Radiology (ACR) Thyroid Imaging, Reporting an...
Racial Differences in Outcomes Among Patients with Multiple Myeloma Treated at a Myeloma Center of Excellence: A Retrospective Cohort Study [0.03%]
多发性骨髓瘤卓越治疗中心患者的结局种族差异：回顾性队列研究
Jordan Lee Cottrell,Anton Casillas,Kingsley C Nnawuba et al.
Jordan Lee Cottrell et al.
Multiple myeloma (MM) is a hematologic malignancy of monoclonal plasma cells. Black individuals have a higher incidence of MM than other races, and numerous studies have described potential disparities in myeloma care. In this retrospective...
Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy [0.03%]
重新定义寡转移性胰腺导管腺癌：生物学、诊断和精准综合治疗
Takehiro Okabayashi,Motoyasu Tabuchi,Teppei Tokumaru et al.
Takehiro Okabayashi et al.
Background: Given the dismal prognosis of metastatic pancreatic ductal adenocarcinoma, oligometastatic disease (OM-PDAC) has emerged as a distinct clinical entity, challenging systemic-only paradigms via advanced multimod...
Sub-National Disparities in the Incidence of Cancers Associated with Modifiable Risk Factors: An Analysis of Canadian CiNA Data (2010-2022) [0.03%]
与可改变的风险因素相关的癌症发病率的亚国家差异：加拿大CiNA数据（2010-2022）分析
Omar Abdel-Rahman
Omar Abdel-Rahman
Objective: To examine subnational disparities between Canadian territories and provinces [covered in the Cancer in North America (CiNA) dataset] in the incidence of cancers grouped by association with modifiable risk fact...
Systematic Investigation of Key Drivers of Lung Adenocarcinoma: A Focus on Genes, Pathways, and miRNAs [0.03%]
肺癌腺癌驱动基因、信号通路及微小RNA的系统分析研究聚焦于基因、途径和miRNA
Maryam Navaei,Fatemeh Karami,Aria Jahanimoghadam et al.
Maryam Navaei et al.
Lung cancer remains a leading cause of cancer-related mortality worldwide, largely due to its asymptomatic progression in early stages and the development of drug resistance. Non-small cell lung cancer (NSCLC) accounts for 80% of all lung c...
Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System [0.03%]
基于FDA不良事件报告系统的伊马替尼相关免疫性不良反应特征分析——20年的真实世界安全性研究
Yongfeng Zhu,Yanbin Zeng,Wanlong Lin et al.
Yongfeng Zhu et al.
Background: Emerging evidence suggests that imatinib may influence immune pathways and be associated with adverse events (AE) with potential immune involvement, some leading to treatment interruption or irreversible damag...
Biomarker-Guided Adjuvant Therapy in Stage II/III Colon Cancer: A Systematic Review of Current Evidence and Clinical Implications [0.03%]
基于生物标志物的辅助治疗在II/III期结肠癌中的应用：现有证据和临床意义的系统性综述
Nabil Ismaili
Nabil Ismaili
Background: The management of resectable stage II/III colon cancer (CC) has long relied on clinicopathological features and fluoropyrimidine-based adjuvant chemotherapy. However, this approach fails to capture the profoun...
Shuaijun Zou,Ruiqian Yao,Xiaoyan Yang et al.
Shuaijun Zou et al.
The elevated incidence of second primary tumors (SPTs) has been reported in certain subtypes of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs), but remains unclear for overall primary cutaneous lymphomas (PCLs). U...